BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16932066)

  • 21. HER-2 gene amplification in Paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study.
    Bianco MK; Vasef MA
    Diagn Mol Pathol; 2006 Sep; 15(3):131-5. PubMed ID: 16932067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Jun; 123(6):889-95. PubMed ID: 15899781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Detection of HER-2/neu in breast carcinoma].
    Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
    Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
    Shafizadeh N; Grenert JP; Sahai V; Kakar S
    Hum Pathol; 2010 Apr; 41(4):485-92. PubMed ID: 20040392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
    Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
    Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix.
    Rosty C; Couturier J; Vincent-Salomon A; Genin P; Fréneaux P; Sigal-Zafrani B; Sastre-Garau X
    Int J Gynecol Pathol; 2004 Jan; 23(1):13-7. PubMed ID: 14668544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
    Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Hirano M; Hayashida K; Mizumukai E; Nanaura H; Honda N
    Oncol Rep; 2007 Nov; 18(5):1183-7. PubMed ID: 17914570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
    Larsimont D; Di Leo A; Rouas G; Paesmans M; Ferreira-Filho F; Bernard C; Cardoso F; Verhest A; Piccart MJ; Gancberg D
    Anticancer Res; 2002; 22(4):2485-90. PubMed ID: 12174949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
    Lin F; Shen T; Prichard JW
    Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
    Di Palma S; Skálová A; Vanìèek T; Simpson RH; Stárek I; Leivo I
    Histopathology; 2005 Feb; 46(2):144-52. PubMed ID: 15693886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ; Hyjek E; Early E; Knowles DM
    Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
    Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
    Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.
    Vang R; Cooley LD; Harrison WR; Reese T; Abrams J
    Am J Clin Pathol; 2000 May; 113(5):669-74. PubMed ID: 10800399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.